My research is focused on the development of novel contrast agents for molecular imaging of cancer. Of particular interest is targeting prostate-specific membrane antigen for the diagnosis of prostate cancer. I’ve been working on prostate-specific membrane antigen for over 14 years, and have successfully developed new chemotherapeutic agents and image agents targeting PSMA. We have rationally designed a highly negatively charged PSMA ligand with binding affinity in nM range. Based on this ligand we synthesized PSMA targeting NIR contrast agents, which can bind specifically to PSMA and can help create highly defined boundaries of the tumor. More recently we also developed PSMA targeting theranostic agents. These agents have shown the ability to effectively inhibit tumor growth in vivo.